IRADIMED CORPORATION Reports First Quarter 2026 Financial Results

IRADIMED CORPORATION announced its financial results for the first quarter ended March 31, 2026. The company reported revenue of $22.0 million, a 13% increase compared to the same period in 2025. GAAP diluted EPS was $0.45 and non-GAAP diluted EPS was $0.49, increases of 22% and 17% respectively. The company declared a quarterly cash dividend of $0.20 per share. The launch of the next-generation 3870 MRI-compatible IV infusion pump system was a significant milestone, with strong early order activity. The company reaffirms its full-year 2026 guidance for revenue between $91.0 million and $96.0 million, and GAAP diluted EPS between $1.90 and $2.05.